This article was originally published in Lookout.
This story has been updated with new information, including that AZ Blue has reversed their decision to remove certain HIV medications and preventative options from their 2027 Affordable Care Act formularies.
Arizona’s largest medical insurer has backed off an earlier decision to drop multiple HIV drugs from its coverage for those who get their insurance through the Affordable Care Act, which would have potentially led to thousands of people with fewer options for care in a state where HIV cases are rising even as they fall in other parts of the country.
The reversal came late Thursday night to now include HIV medications back on their 2027 formularies, including preventative drugs.
The move was a dramatic shift in policy from just a month ago, when patients were the first to alert their doctors they had been informed through letters from AZ Blue, also known as Blue Cross Blue Shield of Arizona, that their medications were no longer being covered.
A letter a clinic patient shared with LOOKOUT shows AZ Blue would no longer cover the pill form of Yeztugo, a preventive medication that must be taken alongside an injection and is more than 99% effective.
Dovato, a daily single-tablet HIV treatment, was also identified as being removed from coverage in other patient letters shared with LOOKOUT. The insurer sent notices warning of the changes as recently as Oct. 30.
After probing from LOOKOUT, AZ Blue said on Thursday it would retain one HIV treatment on its 2027 Affordable Care Act formulary, Biktarvy, but did not address other questions, including whether the changes apply to employer-sponsored plans or only those purchased through the marketplace by individuals.
After publishing on Friday morning, AZ Blue reached out to clarify that all HIV medications would be covered under the 2027 ACA plans.
Health care advocates raised considerable concerns about the potential treatment disruptions.
As of this year, more than 353,000 Arizonans were enrolled in Affordable Care Act marketplace plans. It’s unclear how many of those people use coverage for HIV medications, including preventive care, which has seen significant uptake, primarily among gay, bisexual and other men who have sex with men.
Arizona isn’t the first state where a Blue Cross Blue Shield insurer has faced scrutiny over HIV medication coverage. In June, Mississippi Today reported that Blue Cross and Blue Shield of Mississippi expanded coverage for two HIV prevention medications, known as pre-exposure prophylaxis or PrEP: the daily prevention pill Descovy and 6-times-a-year injectable Apretude. The HIV and Hepatitis Policy Institute filed a complaint alleging the insurer was violating federal coverage requirements. (In 2024, federal coverage requirements expanded to require insurance companies to cover long-acting prevention protocols.)
The reversal was only partial. According to the HIV and Hepatitis Policy Institute, the insurer still classified two long-acting injectables as medically unnecessary: Yeztugo, an HIV prevention drug that can be given as few as twice a year, and Cabenuva, an HIV treatment built on the same active drug as Apretude.
The turnaround in AZ Blue’s policy and surrounding concerns from providers and patients come as Maricopa County continues to grapple with rising HIV diagnoses. According to the county’s Department of Public Health, new HIV/AIDS cases increased by 34% between 2020 and 2024, climbing from 474 to 635.
Maricopa County remains a priority jurisdiction under the CDC’s initiative to end the HIV epidemic, making continued access to treatment and prevention particularly consequential.
Statewide, the trend is similar: In 2021, there were 776 new diagnoses of the virus. Most recently available numbers from 2024 show an increase to 904 cases that year.
Jessyca Leach, CEO of Prisma Community Care, said the decision to remove coverage of the medications “flew almost completely under the radar” until patients brought it to the clinic’s attention, and that the clinic received no prior notice from the insurer.
“We’re turning around and telling folks the care that has been life-giving for you and has allowed you to thrive is being taken away from you,” Leach said. “This makes me feel like we’re back in the ’90s.”
Prisma staff members were preparing to help patients navigate alternatives and coverage exceptions, in addition to their regular work. The clinic has about four patient navigators and recently added two community health workers to assist, Leach said.
Leach explained that many employers close their open enrollment periods in November, after selecting their insurance carriers in September and October. That means some workers may have already committed to a 2027 health plan before learning that their medications could have lost coverage.
Had the exclusions gone forward, Leach also worried that other insurance companies would follow suit: “What happens if they get this across and they’re allowed to do it, are other insurance companies going to look at doing the exact same thing?” Leach said.
Leach said as of Friday morning that their clinic was made aware of AZ Blue’s reversal.
Stacey Jay Cavaliere, executive director of Aunt Rita’s Foundation, an Arizona nonprofit supporting people affected by HIV, drew attention to the “concerning” timing of the decision and notices, which arrived during the holiday season and, for some patients, after their employers’ insurance enrollment deadlines had passed.
“That could potentially limit their ability to explore alternative coverage before these changes take place,” Cavaliere said.
According to the Department of Health and Human Services, for people purchasing insurance through the ACA Marketplace, Dec. 15 is the deadline to select coverage beginning Jan. 1. Although open enrollment continues through Jan. 15, plans selected after Dec. 15 generally would not take effect until February, potentially leaving patients navigating coverage exceptions or alternative medications in January.
Speaking to LOOKOUT before the reversal decision, Calvaliere said that decisions like AZ Blue’s could have had consequences for care later on: “Just speaking broadly, any time a precedent is set by one entity, others tend to follow.”
The decision to limit choices for people currently prescribed HIV medications could have resulted in “nightmare” effects, said Emily Snyder, an HIV specialist and nurse practitioner at Prisma.
Even with newer treatments such as Biktarvy and Dovato, which have fewer side effects, switching medications takes time and care, she said.
“Forcing a patient to switch regimens can lead to their HIV being unmanaged and potential complications from starting a new medication with new side effects,” Snyder said. “If their viral load becomes detectable, that puts them at risk of developing AIDS and becoming at risk of opportunistic infections.”
The greater concern, she said, is an interruption in treatment altogether, which can allow the virus to rebound and potentially develop resistance to the medication.
“Gaps in treatment are our biggest nightmare in the HIV world,” Snyder said. “As little as one week of a missed medication can cause a patient’s viral load to become detectable.”

